INBRAIN Neuroelectronics has made history by performing the world’s first human procedure using its cortical brain-computer interface (BCI) in a patient undergoing brain tumor resection at Salford Royal Hospital in Manchester, UK.
This pioneering technology made surgeons distinguish between healthy and cancerous brain tissue with exceptional precision. INBRAIN’s BCI utilizes graphene, a material known for its strength and unique electronic properties.
Despite being incredibly thin, graphene has proven to be ideal for neurotechnology innovation. It provides high-density sensing and stimulation, allowing for precise tumor removal while preserving critical patient functions such as movement and language.
The first-in-human study, sponsored by the University of Manchester and funded by the European Commission’s Graphene Flagship project, aims to demonstrate the safety of graphene in direct contact with the human brain. The study involves 8-10 patients, and researchers believe graphene will outshine other materials in decoding brain activity in both awake and asleep states.
The success of INBRAIN’s BCI technology marks a significant advancement in precision surgery and neurotechnology. It paves the way for advancements in neural decoding and therapeutic interventions, offering hope for improved outcomes in brain tumor treatment and other neurological conditions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.
